Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
  •   Etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study

Jokinen, Jukka; Rinta-Kokko, Hanna; Siira, Lotta; Palmu, Arto; Virtanen, Mikko J; Nohynek, Hanna; Virolainen-Julkunen, Maija; Toropainen, Maija; Nuorti, Pekka J (2015)

 
Avaa tiedosto
impact_of_ten-valent_2015.pdf (443.8Kt)
Lataukset: 



Jokinen, Jukka
Rinta-Kokko, Hanna
Siira, Lotta
Palmu, Arto
Virtanen, Mikko J
Nohynek, Hanna
Virolainen-Julkunen, Maija
Toropainen, Maija
Nuorti, Pekka J
2015

Plos ONE 10 3
1-11
Terveystieteiden yksikkö - School of Health Sciences
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
doi:10.1371/journal.pone.0120290
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:uta-201504151275

Kuvaus

Public Library of Science open access
Tiivistelmä
The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Program (NVP) in September 2010 with a 2+1 schedule (3, 5, 12 months) without catch-up vaccinations. We evaluated the direct and indirect effects of PCV10 on invasive pneumococcal disease (IPD) among children ≤5 years of age during the first three years after NVP introduction.
Methods

We conducted a population-based, observational follow-up study. The cohort of vaccine-eligible children (all children born June 1, 2010 or later) was followed from 3 months of age until the end of 2013. For the indirect effect, another cohort of older children ineligible for PCV10 vaccination was followed from 2011 through 2013. Both cohorts were compared with season- and age-matched reference cohorts before NVP introduction. National, population-based laboratory surveillance data were used to compare culture-confirmed serotype-specific IPD rates in the vaccine target and reference cohorts by using Poisson regression models.
Results

The overall IPD rate among vaccine-eligible children was reduced by 80% (95%CI 72 to 85); the reduction in vaccine-type IPD was 92% (95%CI 86 to 95). However, a non-significant increase in non-vaccine type IPD was observed. During 2012–2013, we also observed a 48% (95%CI 18 to 69) reduction in IPD among unvaccinated children 2 to 5 years of age, which was mostly attributable to the ten vaccine serotypes.
Conclusions

This is the first population-based study investigating the impact of PCV10 introduction without prior PCV7 use. A substantial decrease in IPD rates among vaccine-eligible children was observed. A smaller and temporally delayed reduction among older, unvaccinated children suggests that PCV10 also provides indirect protection against vaccine-type IPD. Changes in serotype distribution warrant continuous monitoring of potential increases in non-vaccine serotypes.
Kokoelmat
  • Artikkelit [6095]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Yhteydenotto | Tietosuoja | Saavutettavuusseloste